Entos Pharmaceuticals
San Diego, California, United States · Biotechnology, Genetics, Health Care
Entos Pharmaceuticals is a clinical-stage genetic medicines company focused on developing cures and improving patients' lives using its proprietary Fusogenix™ PLV™ technology. The company aims to address rare genetic disorders through innovative genetic medicine approaches. Since its founding in 2016, Entos has been committed to advancing next-generation genetic medicines.
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 44
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Private
- Website
- entospharma.com
- Company page
Recent activity at Entos Pharmaceuticals
- : CureDuchenne Ventures invests in Entos Pharmaceuticals to support the development of a muscle-targeting therapeutic for Duchenne muscular dystrophy (DMD). The funding amount was not disclosed.
- : Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics
- : Entos Pharmaceuticals awarded $4 million in grant funding from CIRM to support its congenital generalized lipodystrophy program.
Entos Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| May 2025 | Funding Round | Undisclosed |
| Feb 2025 | Seed | $4.0M |
Leadership
- Kimberly B. Henshaw, Chief of Staff
- Steve Chen, Chief Medical Officer
- Jason Ding, Chief Business Officer
Verified email and direct lines for Entos Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Entos Pharmaceuticals in the news
- Entos Pharmaceuticals and the L-CMD Research Foundation Collaborate to Develop Curative Therapy for LMNA-Related Congenital Muscular Dystrophy - Business Wire (Apr 20, 2026)
- Entos Pharmaceuticals opens California facility - Manufacturing Dive (Feb 01, 2024)
- CureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene Therapy - PR Newswire Canada (May 22, 2025)
- Oisín Biotechnologies Announces Publication of Preclinical Data from its Muscle Building Gene Therapy Program in Cell - BioSpace (Sep 11, 2024)
- Entos Pharmaceuticals announces research, development and collaboration agreement - EurekAlert! (Oct 02, 2019)
- Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications - Eli Lilly (Jan 06, 2022)
- Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics - Business Wire (Mar 11, 2025)
- Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals, collaborate on Genetic Medicines Project with support from UKRI Innovate UK and Canadian R&D Funding - PR Newswire Canada (Jan 06, 2026)
Companies similar to Entos Pharmaceuticals
- Typewriter Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
- AAVantgarde Bio · Biotechnology, Genetics, Health Care, Therapeutics
- Epicrispr Biotechnologies · Biotechnology, Genetics, Health Care, Therapeutics
- MeiraGTx Holdings plc · Biotechnology, Genetics, Health Care, Therapeutics
- Genetix Biotherapeutics · Biotechnology, Genetics, Health Care, Therapeutics
About Entos Pharmaceuticals: questions and answers
What does Entos Pharmaceuticals do?
Entos Pharmaceuticals is a clinical-stage genetic medicines company focused on developing cures and improving patients' lives using its proprietary Fusogenix™ PLV™ technology. The company aims to address rare genetic disorders through innovative genetic medicine approaches. Since its founding in 2016, Entos has been committed to advancing next-generation genetic medicines.
Where is Entos Pharmaceuticals headquartered?
Entos Pharmaceuticals is headquartered in San Diego, California, United States.
How many employees does Entos Pharmaceuticals have?
Entos Pharmaceuticals has about 44 employees.
Has Entos Pharmaceuticals raised funding?
Yes. Fundz has recorded 2 funding events for Entos Pharmaceuticals. The most recent, Funding Round of Undisclosed, was in May 2025.
What is the latest news on Entos Pharmaceuticals?
On May 22, 2025, CureDuchenne Ventures invests in Entos Pharmaceuticals to support the development of a muscle-targeting therapeutic for Duchenne muscular dystrophy (DMD). The funding amount was not disclosed.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy